SCHEMBL1488093

SCHEMBL1488093

CNCCCSC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8374890 0.91
SCHEMBL22268681 0.88 EPHX1 (0.50)
SCHEMBL21099683 0.88 EPHX1 (0.50)
SCHEMBL19226301 0.88 EPHX1 (0.50)
SCHEMBL22268690 0.88 EPHX1 (0.50)
SCHEMBL179671 0.80
SCHEMBL15371820 0.78 CYP2C19 (0.38)
SCHEMBL14698757 0.78 EPHX1 (0.43)
Hydrochloric Acid SCHEMBL4159363 0.78
SCHEMBL20671609 0.73 KISS1R (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279241-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS CAPABLE OF INHIBITING KRAS MUTANT PROTEINS REDX PHARMA PLC (GB) 2024-08-22 US disclosed
US-20230242548-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ NATIONAL INSTITUTES OF HEALTH 2023-05-11 US disclosed
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 WO disclosed
US-20230131260-A1 SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS SYNGENTA CROP PROTECTION AG (CH) 2023-04-27 US disclosed
US-11597699-B2 MEK inhibitors and methods of their use EXELIXIS, INC. (US) 2023-03-07 US disclosed
EP-4026831-A1 PIPERIC ACID DERIVATIVE AND APPLICATION THEREOF Shenyang Sinochem Agrochemicals R&D Co., Ltd. (CN) 2022-07-13 EP disclosed
WO-2022133114-A1 FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES FMC CORPORATION (US) 2022-06-23 WO disclosed
WO-2022096636-A1 GLP-1 PRODRUGS AND USES HEREOF NOVO NORDISK A/S (DK) 2022-05-12 WO disclosed
CN-109053523-B Azetidines as MEK inhibitors for the treatment of proliferative diseases 埃克塞利希斯股份有限公司 2022-03-25 CN disclosed
US-7358370-B2 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide SERENEX, INC. (US) 2008-04-15 US disclosed
US-20070142351-A1 Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands AVENTIS PHARMACEUTICALS INC. (US) 2007-06-21 US disclosed
US-20070142351-A1 Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands AVENTIS PHARMACEUTICALS INC. (US) 2007-06-21 US disclosed
WO-2007044515-A1 AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2007-04-19 WO disclosed
EP-1749827-A1 ANTI-TUMOR AGENT KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-07 EP disclosed
US-20070021468-A1 Preparation and use of 2-substituted-5-oxo-3-pyrazolidinecarboxylates FMC CORPORATION 2007-01-25 US disclosed
US-5411989-A Cardiovascular disorders BOEHRINGER MANNHEIM, GMBH (DE) 1995-05-02 US disclosed
US-4322342-A Analgesic compounds ELI LILLY AND COMPANY (US) 1982-03-30 US disclosed
US-4259234-A OLIGOPEPTIDES FOR PARENTERAL ADMINISTRATION ELI LILLY AND COMPANY (US) 1981-03-31 US disclosed
US-4199568-A Tetrapeptide amides RECKITT & COLMAN PRODUCTS LIMITED (GB) 1980-04-22 US disclosed